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2001.—The present study investigated whether development
or maintenance of a relatively increased fat mass in normal-
weight patients with chronic obstructive pulmonary disease
(COPD), despite periods of weight loss, may be related to
impaired b-adrenoceptor-mediated responses in lipid utiliza-
tion and thermogenesis. Nine COPD patients and nine
healthy controls (body mass index: 23.0 6 1.3 vs. 23.8 6 0.6
kg/m2, not significant; fat mass: 19.0 6 2.1 vs. 11.9 6 1.5 kg,
P , 0.01) received consecutive 30-min infusions of 6, 12, and
24 ng zkg fat free mass21 zmin21 isoproterenol. During b-ad-
renergic stimulation, nonesterified fatty acid levels increased
significantly less in COPD patients (P , 0.001). Respiratory
exchange ratio decreased similarly in both groups, indicating
a similar change in the rate of lipid to carbohydrate oxida-
tion. Energy expenditure increased similarly in both groups
during b-adrenergic stimulation. However, because plasma
isoproterenol concentrations were significantly higher in
COPD patients, thermogenesis related to isoproterenol con-
centration was significantly reduced in this group (P , 0.05).
In conclusion, b-adrenoceptor-mediated lipolysis and ther-
mogenesis are impaired in COPD patients. This may play a
role in the development or maintenance of their relatively
increased fat mass.
sympathetic nervous system; fat mass; energy expenditure
WEIGHT LOSS COMMONLY OCCURS in patients with chronic
obstructive pulmonary disease (COPD), in particular
in the emphysematous subtype (12). Different patterns
of body compositional changes are observed in these
patients. Although normal weight loss merely com-
prises loss of fat and fat-free mass, COPD patients may
show a depletion of fat-free mass despite a relative
preservation of fat mass (2, 10). In the latter group,
functional capacity characterized by decreased muscle
function, exercise capacity, and even health status is
more impaired compared with underweight subjects
with a normal fat-free mass (28). Furthermore, recent
studies indicate that the relative or absolute increase
in fat mass and decrease in fat-free mass in COPD
patients might be related to intrinsic deviations in
substrate metabolism, such as an impaired lipolytic
response during exercise or insulin infusion (17, 19, 20)
and an increased fasting protein turnover (11).
A blunted b-adrenergic response might also play a
role in the development or maintenance of an increased
fat mass (5). During the infusion of isoproterenol (a
nonselective b-adrenoceptor agonist), obese men
showed an impaired response in lipolysis and lipid
oxidation compared with lean men (3), which favors the
development or maintenance of their increased fat
mass. Furthermore, when very obese men were com-
pared with very lean men, an impaired thermogenic
response was found as well (6). After a weight loss
period, these parameters remained impaired (5), sug-
gesting that a diminished capacity to utilize fat may be
a primary factor leading to the development of obesity
rather than a secondary factor as a result of the obese
state.
The relatively increased fat mass in normal-weight
patients with COPD might also be explained by a
primary impaired response to b-adrenergic stimula-
tion but may also be secondary to their disease or its
treatment. COPD patients with emphysema have
increased plasma norepinephrine levels at rest (14),
suggesting an overstimulation of the sympathetic
nervous system (SNS) in the basal state, whereas
their chronic b2-adrenoceptor agonist use for bron-
chodilation causes downregulation of SNS respon-
siveness (33, 43). Furthermore, several studies
showed a decreased oxidative capacity in peripheral
skeletal muscle that could blunt lipid utilization and
thermogenesis (18, 25).
The aim of the present study was to investigate
whether development or maintenance of a relatively
increased fat mass in normal-weight patients with
COPD, despite periods of weight loss, is related to an
impaired response in lipid utilization and thermogen-
esis induced by b-adrenergic stimulation with isopro-
terenol.
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SUBJECTS AND METHODS
Subjects. Nine male COPD patients with moderate to se-
vere emphysema and nine healthy male age-matched control
subjects participated in this study. COPD was diagnosed
according to the criteria of the American Thoracic Society (1),
and macroscopic emphysema was diagnosed by high-resolu-
tion computed tomography. All patients were in clinically
stable condition and were weight stable for $3 mo. However,
on average they had lost 3–4 kg body wt in the year preced-
ing the experiment. Patients used inhaled b2-sympathicomi-
metica and inhaled corticosteroids. In the 24 h preceding the
study, patients were not allowed to use any sympathicomi-
metic drugs to prevent any acute effect of these drugs on
energy metabolism. Control subjects were in good health as
assessed by medical history and physical examination, and
none used b2-sympathicomimetic drugs. Data on whole body
thermogenesis of the control group have been published pre-
viously (21). Both patients and controls spent no more than 2
h/wk in organized sports activities; none of the subjects had
a history of hypertension, cardiovascular disease, or heart
failure. Patients were all ex-smokers, and controls were non-
smokers. The study protocol was reviewed and approved by
the Ethics Committee of Maastricht University, and all sub-
jects gave informed consent before participating in the study.
Experimental design. Subjects were studied in the morning
after an overnight fast. They came to the laboratory by car or
by bus to minimize the amount of physical activity before the
test. On arrival, a cannula was inserted into a forearm vein
of each arm. One cannula was used for the infusion of drugs
and the other cannula for the sampling of blood. All measure-
ments were done with the subject in supine position, and
room temperature was kept at 21–23°C. The study protocol
consisted of four study periods. After a 30-min baseline
measurement, subjects received consecutive infusions of 6,
12, and 24 ng zkg fat-free mass (FFM)21 zmin21 isoproterenol
(Isoprenaline sulfate, Fresenius, ’s Hertogenbosch, The Neth-
erlands), each dose for 30 min. At the end of each 30-min
period, a blood sample was taken.
Clinical methods. Body composition of COPD patients was
measured by single frequency (50 kHz) bioelectrical imped-
ance analysis (Xitron Technologies, San Diego, CA) with the
subject in supine position. FFM was calculated according to
the equation of Schols et al. (36), validated for this group of
patients. Body density of the control group was determined
by hydrostatic weighing with simultaneous lung volume
measurement (Volugraph 2000, Mijnhardt, Bunnik, The
Netherlands), and body composition was calculated accord-
ing to the equation of Siri (38).
In patients with COPD, lung function was measured be-
fore the isoproterenol infusion test. Forced expiratory volume
in 1 s (FEV1) and inspiratory vital capacity (IVC) were
calculated from the flow-volume curve by use of a spirometer
(Jaeger, Hoechberg, Germany). Lung function was expressed
as percentage of reference value (29).
Whole body energy expenditure and respiratory exchange
ratio (RER) were measured by an open-circuit ventilated
hood system (Oxycon beta, Mijnhardt, Bunnik, The Nether-
lands). The airflow rate and the O2 and CO2 concentrations of
the in- and outflowing air were used to compute O2 consump-
tion and CO2 production on-line through an automatic acqui-
sition system connected to a personal computer. Energy ex-
penditure was calculated according to the formula proposed
by Weir (42). Energy expenditure and RER values were
averaged over the last 10 min of each 30-min period during
which steady state occurred.
Heart rate was monitored continuously by conventional
electrocardiography, and the mean value over the last 10 min
of each 30-min period was used for further analysis.
Analytical methods. Blood samples for the determination
of nonesterified fatty acids (NEFA), glucose, and insulin were
preserved in sodium-EDTA and those for isoproterenol, nor-
epinephrine, and epinephrine determination were preserved
in heparin plus glutathione (1.5% wt/vol). Blood samples
were immediately centrifuged for 10 min at 800 g at 4°C.
Plasma was transferred into microtest tubes, rapidly frozen
in liquid nitrogen, and stored at 270°C until further analy-
sis. Plasma NEFA concentration was measured with the
NEFA C kit (99475409, WAKO, Neuss, Germany), and
plasma glucose concentration was measured with a glucose
kit (Unimate 5, 0736724, Roche Diagnostica, Basel, Switzer-
land), both on a Cobas-Fara centrifugal analyzer (Roche
Diagnostica). Plasma insulin concentration was determined
with a double antibody radioimmunoassay (Insulin RIA 100,
Pharmacia, Uppsala, Sweden). Plasma isoproterenol, norepi-
nephrine, and epinephrine levels were determined by high-
performance liquid chromatography according to the method
of Smedes et al. (39). Standard samples with known concen-
trations were included in each run for quality control.
Data analysis. All data are presented as means 6 SE. Data
for energy expenditure were adjusted for FFM for group
comparison using linear regression analysis (30).
To summarize the response of each subject to isoproterenol
infusion in a single value, b-adrenergically mediated thermo-
genesis was expressed as the dose and the plasma concen-
tration of isoproterenol required to increase baseline energy
expenditure by 15% (doseDEE515% and concDEE515%, respec-
tively) (6). To evaluate the b-adrenergically-mediated heart
rate response, both the chronotropic dose (CD25) and the
chronotropic concentration (CC25) were calculated from the
dose and plasma concentration of isoproterenol required to
increase basal heart rate by 25 beats/min (26). These values
were determined by applying individual linear regression
analysis to the measured response vs. the dose or plasma
concentration of isoproterenol.
The effect of b-adrenergic stimulation between groups was
analyzed with two-way repeated-measures ANOVA. Post hoc
testing between groups was done with an unpaired t-test.
The effect of b-adrenergic stimulation within a group was
analyzed with one-way repeated-measures ANOVA. A P
value ,0.05 was regarded as statistically significant.
RESULTS
Physical characteristics of the subjects are given in
Table 1. Body weight and body mass index were similar
in the two groups. Although patients with COPD had
lost 3–4 kg body wt in the year preceding the experi-
ment, they had a significantly higher fat mass (P ,
0.01) and a significantly lower FFM (P , 0.05) com-
pared with control subjects.
Plasma isoproterenol concentrations significantly in-
creased during isoproterenol infusion in COPD pa-
tients and control subjects but were significantly
higher in the patient group (Fig. 1). At baseline,
plasma norepinephrine levels were significantly higher
(P , 0.05) and plasma epinephrine levels were slightly
lower (P 5 0.06) in patients compared with controls.
During b-adrenergic stimulation with isoproterenol,
norepinephrine concentrations significantly increased
and epinephrine concentrations significantly de-
creased in both groups. The changes in norepinephrine
E358 b-ADRENERGIC STIMULATION IN COPD
and epinephrine levels were comparable between
groups (Fig. 1).
At baseline, plasma NEFA concentrations were sim-
ilar in patients and controls (Fig. 2). However, the
increase in plasma NEFA concentration was signifi-
cantly reduced (P , 0.001) in patients with COPD
despite the greater increase in plasma isoproterenol
concentration, suggesting a blunted b-adrenergically
mediated lipolytic response. Plasma glucose and insu-
lin levels were similar in both groups at baseline.
Glucose and insulin levels significantly increased dur-
ing b-adrenergic stimulation, but these increases were
not significantly different between groups (Table 2).
Baseline energy expenditure was slightly lower in
patients with COPD compared with controls (4.71 6
0.24 vs. 5.21 6 0.22 kJ/min, P 5 0.14), but after
adjustment for FFM, baseline energy expenditure was
similar in both groups (Fig. 2). During b-adrenergic
stimulation, energy expenditure significantly in-
creased in both groups. There was no significant dif-
ference in the increase in energy expenditure between
COPD patients and control subjects. In addition,
doseDEE515% was not different between groups (Table
3). However, when responses were related to plasma
isoproterenol concentrations, concDEE515% was signifi-
cantly higher (P , 0.05) in patients compared with
controls, indicating a blunted b-adrenergically medi-
ated thermogenic response in patients with COPD
(Fig. 3 and Table 3). RER was similar in both groups at
baseline and significantly decreased with isoprotere-
nol, indicating a similar change in the rate of lipid to
carbohydrate oxidation during b-adrenergic stimula-
tion (Table 2).
Heart rate was comparable in patients and controls
at baseline and similarly increased during b-adrener-
gic stimulation (Fig. 2). Thus CD25 was not signifi-
cantly different between groups. When heart rate re-
sponses were related to plasma isoproterenol
concentrations, CC25 was slightly higher in patients
with COPD, but this difference did not reach statistical
significance (P 5 0.11; Fig. 3 and Table 3).
DISCUSSION
The present study intended to investigate whether
development or maintenance of a relatively increased
fat mass in normal-weight patients with COPD, de-
spite periods of weight loss, is related to a blunted
increase in lipid utilization and thermogenesis during
b-adrenergic stimulation with isoproterenol. It was
found that the b-adrenoceptor-mediated increase in
NEFA concentration was impaired in COPD patients,
Fig. 1. Plasma isoproterenol, norepinephrine, and epinephrine con-
centrations during b-adrenergic stimulation with isoproterenol.
FFM, fat-free mass. Values are means 6 SE for 9 chronic obstructive
pulmonary disease (COPD) patients () and 9 healthy controls (n ).
One-way repeated-measures ANOVA: #P , 0.05, ###P , 0.001; un-
paired t-test, COPD vs. control: *P , 0.05, ***P , 0.001.
Table 1. Physical characteristics of COPD patients
and control subjects
Parameter COPD Control
Body weight, kg 71.7(39.0–88.9) 73.5(66.5–85.9)
Height, m 1.76(1.58–1.93) 1.76(1.68–1.88)
Body mass index, kg/m2 23.0(15.6–29.2) 23.8(21.6–27.5)
Fat mass, kg 19.0(6.4–30.2)** 11.9(6.3–19.9)
FFM, kg 52.7(32.6–66.5)* 61.6(53.6–71.8)
Age, yr 55(49–62) 51(41–58)
FEV1, % predicted 36(16–65)
IVC, % predicted 84(33–150)
Values are means (range) for 9 chronic obstructive pulmonary
disease (COPD) patients and 9 control subjects. FFM, fat-free mass;
FEV1, forced expiratory volume in 1 s; IVC, inspiratory vital capac-
ity. Unpaired t-test, COPD vs. control: *P , 0.05, **P , 0.01.
E359b-ADRENERGIC STIMULATION IN COPD
indicating a blunted lipolytic response. RER decreased
similarly in both groups, suggesting a similar change
in the rate of lipid to carbohydrate oxidation. b-Adre-
noceptor-mediated thermogenesis was impaired when
related to plasma isoproterenol concentrations. The
impaired release of NEFA from adipose tissue and the
reduced thermogenic response may play a role in the
development or maintenance of relatively increased fat
stores in patients with COPD, even when they lost
weight.
COPD patients and control subjects showed a simi-
lar response in energy expenditure when related to the
dose of isoproterenol infused. However, patients with
COPD had significantly higher plasma isoproterenol
concentrations and thus an impaired thermogenic re-
sponse when related to plasma isoproterenol concen-
tration. The heart rate response was also slightly lower
in patients with COPD when related to plasma isopro-
terenol concentration, but this did not reach statistical
significance. The differences in plasma isoproterenol
concentrations indicate that the pharmacokinetics of
isoproterenol are different in patients compared with
healthy controls. The reason for this is not clear. Dif-
ferences in hepatic or renal clearance are not evident,
since none of the patients or control subjects were
diagnosed with impaired liver or renal function. An-
other explanation might be a reduction in the number
of b-adrenoceptor binding sites. The literature shows
that a reduced b-adrenoceptor number on fat cells
might be a primary factor leading to the development
or maintenance of a relatively increased fat mass (32).
On the other hand, chronic b2-adrenoceptor agonist
administration is also found to reduce the number of
b-adrenoceptors on lymphocytes. Fourteen days of oral
terbutaline administration is known to reduce the lym-
phocyte b-adrenoceptor number by .50% in both nor-
mal subjects and asthmatic patients (13, 40, 41). If the
b-adrenoceptor number is reduced in these and other
tissues and a similar dose of isoproterenol is given to
patients and controls, less isoproterenol can bind to the
available receptors in patients, and as a consequence,
the concentration of free isoproterenol is increased in
the patient group. Furthermore, the significantly
higher plasma isoproterenol concentrations in the pa-
tient group make it clear that individual plasma con-
centration-response curves instead of dose-response
curves should be used in the analysis of these kinds of
experiments, because plasma concentration-response
curves increase the precision of these infusion tests.
This has already been emphasized by others (6, 21, 26).
To our knowledge, this is the first study to report a
blunted isoproterenol-induced increase in plasma
NEFA concentration in COPD patients. However, the
impaired NEFA release might be explained by a de-
creased lipolytic response and/or increased reesterifi-
cation within adipose tissue or other tissues. An im-
paired isoproterenol-induced lipolytic response has
been reported before in obese subjects, both in vivo (3)
and in vitro (31), indicating that this might be an
important explanation for the blunted increase in
NEFA concentration in COPD patients with a rela-
tively increased fat mass.
This is also the first study to report an impaired
thermogenic response in COPD patients with moder-
ate to severe emphysema. Only Creutzberg et al. (9) did
a comparable study in which they measured the acute
Fig. 2. Plasma nonesterified fatty acid (NEFA) concentration, en-
ergy expenditure adjusted for FFM, and heart rate expressed per
dose of isoproterenol infused. Values are means 6 SE for 9 COPD
patients () and 9 healthy controls (n ). One-way repeated-measures
ANOVA: ###P , 0.001; unpaired t-test, COPD vs. control: *P , 0.05,
**P , 0.01.
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thermogenic effect after salbutamol nebulation. They
found no difference in thermogenesis between patients
with COPD and age-matched healthy control subjects.
However, plasma salbutamol levels were not measured
in this experiment, so a possibly reduced thermogenic
response related to plasma salbutamol concentrations
could not be demonstrated. Furthermore, a reduced
isoproterenol-induced increase in thermogenesis has
been reported in obese subjects (6). This blunted re-
sponse might be explained by the impaired lipolytic
response, which leads to a reduced NEFA availability
in the blood. Therefore, less NEFA can be taken up and
oxidized by skeletal muscle, and as a consequence,
thermogenesis may be reduced. This hypothesis is sup-
ported by another study from our group (34), in which
lipolysis was pharmacologically inhibited with acipi-
mox. Concomitant b1-adrenergic stimulation resulted
in a reduced increase in lipolysis and thermogenesis
compared with b1-adrenergic stimulation alone. Fur-
thermore, reduced oxidative capacities in peripheral
skeletal muscle, reported both in obesity (7, 37) and in
COPD (18, 25), might blunt lipid oxidation and ther-
mogenesis.
The blunted b-adrenoceptor-mediated lipolytic and
thermogenic response in patients with COPD might be
a primary factor leading to the development of their
relatively increased fat stores. This might be caused by
an already developed impairment in b-adrenoceptor-
mediated processes before the onset of the disease, as is
the case in obesity. In vitro studies in fat cells from
obese subjects suggest that the impaired lipolytic re-
sponse to isoproterenol is due to a significant reduction
in cell surface density of the b2-adrenoceptor (23, 32).
In an in vivo study (35), we showed that b2-adrenocep-
tor-mediated thermogenesis and lipid utilization are
blunted in obese compared with lean subjects, whereas
b1-adrenoceptor-mediated responses are similar in the
groups.
The blunted b-adrenergic response might also be
secondary to the already developed increased fat
stores. Because abdominal subcutaneous adipose tis-
sue blood flow is reduced in obesity (4), fat cell lipolysis
might not be fully stimulated, leading to a reduced
release of NEFA. Furthermore, due to a possibly re-
duced abdominal blood flow, which is seen in obese
subjects (4), only part of the available NEFA in the
interstitial fluid might be taken up into the blood-
stream, and the remaining part has to be stored again.
These factors might contribute to the maintenance of
relatively increased adipose tissue stores.
Regression analysis showed that there was a signif-
icant relationship between percent body fat and the
increase in plasma NEFA concentration (r 5 20.56,
P , 0.02) and percent body fat and the increase in
plasma isoproterenol concentration (r 5 0.47, P , 0.05)
for the whole group. After reanalysis per subgroup
(patients or controls), these significant relationships
disappeared, probably due to the small number of sub-
jects. Regression analysis between other combinations
of variables, like increase in plasma NEFA concentra-
tion, increase in plasma isoproterenol concentration,
baseline norepinephrine concentration, and percent
body fat revealed no further significant relationships,
either in the whole group or in one of the subgroups.
Whether the impaired b-adrenergic response in pa-
tients with COPD is a cause or a consequence of their
increased fat mass needs to be further explored.
Another explanation for the blunted b-adrenergic
response during isoproterenol infusion in patients with
COPD might be desensitization of the SNS due to the
disease. COPD patients are found to have increased
plasma norepinephrine levels and decreased plasma
epinephrine levels at rest (14). This suggests that sym-
pathetic nerve activity is increased in the basal state.
Table 2. Measured parameters at baseline and during isoproterenol infusion
in COPD patients and control subjects
Parameter Group Baseline
Isoproterenol, ng zkg FFM
21
zmin
21 ANOVA
6 12 24 Treatment
Treatment
group
RER COPD 0.8260.01 0.8360.01 0.8260.01 0.8160.01 P , 0.01 NS
Control 0.8260.01 0.8460.01 0.8160.01 0.8160.01
Glucose, mmol/l COPD 5.2460.21 5.1660.19 5.1260.19 5.3360.18 P , 0.05 NS
Control 5.0060.16 5.0160.12 5.0360.10 5.2260.08
Insulin, mU/l COPD 5.0960.45 6.6360.56 7.2660.71 8.5260.96 P , 0.001 NS
Control 5.8660.97 6.5160.50 7.2260.81 9.3061.40
Values are mean 6 SE for 9 COPD patients and 9 control subjects. RER, respiratory exchange ratio.
Table 3. Energy expenditure and heart rate and their
sensitivity to b-adrenergic stimulation with
isoproterenol in COPD patients and controls
Parameter COPD Control
Baseline energy expenditure
adjusted for FFM, kJ/min
4.9760.13 4.9560.20
DoseDEE515%, ng zkg
FFM21 zmin21
2766 2265
ConcDEE515%, nmol/l 1.8060.32* 0.8560.23
Basal heart rate, beats/min 6564 6364
CD25, ng zkg FFM21 zmin21 2365 2463
CC25, nmol/l 1.4360.25 0.9360.16
Values are means 6 SE for 9 COPD patients and 9 control
subjects. DoseDEE515% and concDEE515%, dose or plasma concentra-
tion of isoproterenol needed to increase thermogenesis by 15%; CD25
and CC25, dose or plasma concentration of isoproterenol needed to
increase heart rate by 25 beats/min. Unpaired t-test, COPD vs.
control: *P , 0.05.
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Because of this chronic overstimulation of the SNS,
b-adrenoceptors may become desensitized, and conse-
quently, the response to additional b-adrenergic stim-
ulation might be blunted.
Finally, the impaired SNS response might be related
to chronic usage of b2-adrenoceptor agonists for bron-
chodilation. In normal subjects, 2 wk of regular salbu-
tamol inhalation induced a blunted increase in plasma
NEFA and glycerol concentrations during salbutamol
infusion (15). Thirteen days of salbutamol inhalation
(43) or 2 wk of oral terbutaline administration (33)
induced impaired thermogenic responses after salbu-
tamol inhalation or isoproterenol infusion, respec-
tively. In COPD patients, the effect of chronic b2-
adrenoceptor agonist usage on thermogenesis and lipid
utilization has never been studied. However, in pa-
tients with moderate (22) to severe (27) asthma, who
also use b2-adrenergic bronchodilators, a blunted in-
crease in plasma NEFA concentration was found dur-
ing epinephrine infusion. Furthermore, in asthmatic
patients using large dosages of b-adrenergic broncho-
dilators, lymphocyte cAMP production during isopro-
terenol incubation was significantly reduced compared
with that in control subjects (8, 40, 41) or in asthmatic
patients on nonadrenergic drugs (8). Moreover, when
the asthmatic patients changed to nonadrenergic
drugs (8) or a placebo (41), their cAMP response to
isoproterenol returned to normal. Furthermore,
Makino et al. (24) showed that lymphocyte cAMP pro-
duction was impaired in asthmatic patients only dur-
ing incubation with salbutamol and not with norepi-
nephrine (b1 . b2-adrenoceptor affinity) compared
with healthy controls. This suggests that chronic b2-
adrenoceptor agonist administration desensitizes only
b2-adrenoceptors and not b1-adrenoceptors.
In our study, patients were asked to stop using their
b2-adrenergic bronchodilators 24 h before the start of
the experiment to prevent any acute interference with
our isoprenaline infusion test. All patients used in-
haled salbutamol [plasma half-time (t1/2) 5 4–6 h] or
inhaled salmeterol (plasma t1/2 unknown due to very
low plasma concentrations after inhalation) for bron-
chodilation. Considering 24-h withdrawal, plasma sal-
butamol concentrations would be ,5% of that directly
after inhalation and therefore will not directly influ-
ence our study. However, the desensitizing effect of
chronic b2-adrenoceptor agonist usage on the mea-
sured parameters is still present after 24-h with-
drawal.
Our COPD patients also chronically inhaled cortico-
steroids, which are known to potentiate the effect of
b-adrenergic stimulation. Hui et al. (16) showed that
the reduction in lymphocyte b-adrenoceptor number
induced by 3–5 wk of oral terbutaline administration
was completely reversed 16 h after a single intrave-
nous dose of methylprednisolone in both normal sub-
jects and asthmatic patients. Furthermore, Reynisdot-
tir et al. (31) showed that lipolytic sensitivity to
isoproterenol in isolated abdominal adipocytes from
asthmatic patients (who only sporadically needed in-
haled b2-adrenoceptor agonists) increased 50-fold after
7 days of oral prednisolone treatment. Sensitivity to
terbutaline increased 25-fold, whereas sensitivity to
dobutamine (b1-adrenoceptor agonist) remained un-
changed after treatment. Furthermore, the number of
b2-adrenoceptor binding sites increased by 60% after
glucocorticosteroid treatment, whereas b1-adrenocep-
tor binding sites were not affected. This suggests that
Fig. 3. Plasma NEFA concentration, energy expenditure adjusted
for FFM, and heart rate expressed per plasma isoproterenol concen-
tration. Values are means 6 SE for 9 COPD patients () and 9
healthy controls ( n ).
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glucocorticosteroids selectively increase b2-adrenocep-
tor density and function and may possibly reverse the
desensitizing effect of chronic b2-adrenoceptor agonist
usage.
In conclusion, b-adrenoceptor-mediated lipolysis and
thermogenesis are reduced in normal-weight patients
with COPD with a relatively increased fat mass com-
pared with healthy age-matched control subjects. The
impaired release of NEFA from adipose tissue and the
reduced thermogenic response may play a role in the
development or maintenance of the relatively in-
creased fat stores in these patients, despite periods of
weight loss.
This study was supported by a grant from The Netherlands
Asthma Foundation, Grant 96.16, and the Dutch Diabetes Research
Foundation.
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